275 nm波长UVC光的皮肤安全性研究

目的探索275 nm C波段紫外线(Ultraviolet C,UVC)光照射对皮肤细胞和血管内皮细胞生存、生长的影响,以及其长期和短期照射对裸鼠皮肤的影响,以确定其安全性。方法设计275 nm UVC-LED光源,分别对人类永生化表皮细胞和人脐静脉内皮细胞进行不同时间的照射,观察不同照射剂量对其生存生长的影响;对裸鼠皮肤进行不同时间的照射,观察外观变化,并收集照射区域组织进行免疫组化分析。结果低剂量275 nm UVC光直接照射细胞时,有一定的皮肤相关细胞安全性。但是高剂量的275 nm UVC光照射会对细胞产生较大伤害。同时,不论是低剂量还是高剂量照射275 nm UVC光均不会诱导裸鼠皮肤DNA损伤和表皮损伤。结论275 nm UVC光具有一定的皮肤安全性,有一定的临床应用前景。

Scalable synthesis of Na_(3)V_(2)(PO_(4))_(3)/C with high safety and ultrahigh-rate performance for sodium-ion batteries

NASICON-type Na_(3)V_(2)(PO_(4))_(3) is a promising electrode material for developing advanced sodium-ion batteries.Preparing Na_(3)V_(2)(PO_(4))_(3) with good performance by a cost-effective and large-scale method is significant for industrial applications.In this work,a porous Na_(3)V_(2)(PO_(4))_(3)/C cathode material with excellent electrochemical performance is successfully prepared by an agar-gel combined with freeze-drying method.The Na_(3)V_(2)(PO_(4))_(3)/C cathode displayed specific capacities of 113.4 mAh·g^(-1),107.0 mAh·g^(-1) and 87.1 mAh·g^(-1) at 0.1 C,1 C and 10 C,respectively.For the first time,the 500-mAh soft-packed symmetrical sodium-ion batteries based on Na_(3)V_(2)(PO_(4))_(3)/C electrodes are successfully fabricated.The 500-mAh symmetrical batteries exhibit outstanding low temperature performance with a capacity retention of 83%at 0℃ owing to the rapid sodium ion migration ability and structural stability of Na_(3)V_(2)(PO_(4))_(3)/C.Moreover,the thermal runaway features are revealed by accelerating rate calorimetry(ARC)test for the first time.Thermal stability and safety of the symmetrical batteries are demonstrated to be better than lithium-ion batteries and some reported sodium-ion batteries.Our work makes it clear that the soft-packed symmetrical sodium ion batteries based on Na_(3)V_(2)(PO_(4))_(3)/C have a prospect of practical application in high safety requirement fields.

Prevalence of Occupational Injury and Knowledge of Post-Exposure Prophylaxis Accessibility among Healthcare Workers in Mogadishu, Somalia

Introduction: Healthcare workers in Mogadishu, Somalia face significant occupational injury risks, particularly needle stick injuries, with 61.1% reporting incidents. This poses a serious threat to their health, leading to infections such as hepatitis B, hepatitis C, and HIV. Despite the high prevalence of injuries, awareness of Post-Exposure Prophylaxis (PEP) accessibility is relatively high, with 84.0% of respondents aware of it. However, there are gaps in knowledge and implementation, as evidenced by variations in availability of PEP. Improving workplace safety measures, providing comprehensive training on injury prevention and PEP protocols, and ensuring consistent availability of PEP in healthcare facilities are crucial steps to safeguard the well-being of healthcare workers in Mogadishu, Somalia. Methods: A cross-sectional study was conducted among hospital workers in Mogadishu, Somalia, focusing on professionals from various healthcare facilities. The study targeted nurses, doctors, laboratory personnel, and pharmacists. Purposive sampling was employed, resulting in a sample size of 383 calculated using Fisher’s sample size formula. Data were collected using coded questionnaires entered into Microsoft Excel 2019 and analyzed with SPSS software to generate frequencies and proportions, presented through frequency tables and pie figures. Results: The study in Mogadishu, Somalia, examined the prevalence of occupational injuries and knowledge of Post-Exposure Prophylaxis (PEP) accessibility among healthcare workers. Findings indicate a high prevalence of injuries, with 61.1% reporting incidents, predominantly needle stick injuries (60.6%). Despite the majority seeking prompt medical attention (72.0%), work-related illnesses affected 53.2% of respondents, notably work-related stress (59.5%). While most received training on injury and illness prevention (68.9%), gaps exist in PEP awareness, with 16.0% unaware of it. Nonetheless, 84.0% were aware, predominantly through health facilities (52.0%). Availability of PEP was reported by 71.3% in healthcare facilities, with variations in shift availability. The majority reported guidelines for PEP use (55.7%). Efforts are needed to bolster PEP awareness and ensure consistent availability in healthcare facilities to safeguard worker health. Conclusion: High prevalence of occupational injuries among healthcare workers, with needle stick injuries being the most common (60.6%). Despite this, 84.0% of respondents were aware of Post-Exposure Prophylaxis (PEP), primarily learning about it from health facilities (52.0%). While 71.3% reported the availability of PEP in their facility, 28.7% noted its unavailability. These results emphasize the need for improved education and accessibility of PEP to mitigate occupational injury risks.

基于C#的大坝强震监测系统

随着西藏经济大发展,国家对西藏水资源开发的投入不断增加,西藏重大水利枢纽工程的论证开发与建设持续推进,发展网络信息共享、兼容性强、数据实时处理的大坝强震监测系统显得愈发重要。本文借助C/S架构,利用Visual C#语言、My SQL数据库与GIS二次开发,构建了一种基于C#的大坝强震监测系统。可以实现联网远程大坝强震信号的实时采集、处理、保存与强震信息空间可视化与数据管理等功能,为管理小组的震后大坝结构性能评估提供决策支撑。

Automatic Modeling of Fault Tree for NuIEEE Transactions on Power Electronics,Clear Power Safety I&C Configuration

The automatic modeling of fault tree for nuclear power safety I&C configuration is designed to meet the requirements of reducing the workload and improving the traceability during the nuclear power safety I&C system reliability assessment work. To complete the fault tree automatic modeling, the Visio Automation software technology is used to analyze the topology of the nuclear power safety I&C system hardware device and software function. The good result in practical implementations shows that the nuclear power safety I&C system fault tree modeling work is successfully simplified.

基于2021版C-NCAP的乘员保护修正项评价结果分析

2021版C-NCAP相较于2018版首次引入了乘员保护修正项目,使车辆乘员保护性能的评价更加全面。本文总结乘员保护修正项评价过程中罚分频率较高的项目及常见的问题,按不同试验及假人类型梳理出现罚分的评价项目。之后解析乘员保护修正项目评价原理,深入分析问题原因,同时给出整改方法供车企被动安全工程师参考。

Real life efficacy and safety of direct-acting antiviral therapy for treatment of patients infected with hepatitis C virus genotypes 1, 2and 3 in northwest China

BACKGROUND Regimens involving direct-acting antiviral agents(DAAs)are recommended for the treatment of infection with hepatitis C virus(HCV)genotypes 1,2 and 3.But real-world data is still not enough,especially in Asia.AIM To investigate the efficacy and safety of DAA-based regimens in a real-life setting in China.METHODS This study included 366 patients infected with HCV genotypes 1,2 and 3,with or without cirrhosis,who were observed between May 2015 and December 2018.They were treated with ledipasvir and sofosbuvir(SOF)(genotype 1)with or without ribavirin(RBV),SOF and RBV(genotype 2),or SOF and daclatasvir(genotype 3),with or without RBV,for 12 or more wk.The participants’sustained virological responses(SVR)at post-treatment week 12(SVR12)was the primary endpoint.The occurrence of adverse events and drug-drug interactions were recorded.RESULTS In the 366 patients,genotype 1(59.0%)was the most common genotype,followed by genotypes 2(34.4%)and 3(6.6%).Liver cirrhosis was diagnosed in 154(42.1%)patients.Fifty(13.7%)patients were treatment-experienced.Intention-to-treat analysis revealed that SVR12 was 86.3%(316/366).For modified intention-totreat analysis,SVR12 was achieved in 96.6%of overall patients(316/327),96.3%in patients with genotype 1,97.5%in those with genotype 2,and 95.0%in those with genotype 3.Most of the treatment failures were due to lack of follow-up(3cases had non-responses,1 had virological breakthrough,11 relapsed and 36 did not participate in the follow-up).There was no significant difference in SVR between different genotypes and liver statuses(P<0.05).Patients with lower alanine aminotransferase levels at baseline who achieved an end of treatment response were more likely to achieve SVR12(P<0.05).High SVR was observed regardless of age,gender,liver status,alpha-fetoprotein,HCV RNA levels or history of antiviral therapy(P>0.05 for all).The cumulative hepatocellular carcinoma occurrence and recurrence rate after using the DAAs was 0.9%.Most of the adverse events were mild.We found two cases of special adverse events.One case involved facial and bilateral lower extremity edema,and the other case showed an interesting change in lipid levels while on medication.No severe adverse events were noted.CONCLUSION The DAA-based regimens tested in this study have excellent effectiveness and safety in all patients infected with HCV genotypes 1,2 and 3,including those with cirrhosis.

Efficacy and safety of pegylated-interferon α-2a in hemodialysis patients with chronic hepatitis C

AIM： To evaluate the efficacy and safety of pegylated- interferon alpha-2a in hemodialysis patients with chronic hepatitis C. METHODS： Thirty-six hemodialysis patients with chronic hepatitis C were enrolled in a controlled and prospective study. All patients were treatment naive, positive tested for anti-HCV antibodies, and positive tested for serum HCV-RNA. Twenty-two patients received 135 μg peglyated-interferon α-2a weekly for 48 wk （group A）. The remaining patients were left untreated, eleven refused therapy, and three were not candidates for kidney transplantation and were allocated to the control group （group B）. At the end of the treatment biochemical and virological response was evaluated, and 24 wk after completetion of therapy sustained virological response （SVR） was assessed. Side effects were monitored. RESULTS： Of 22 hemodialysis patients, 12 were male and 10 female, with a mean age of 35.2 ± 12.1 years. Virological end-of-treatment response was observed in 14 patients （82.4%） in group A and in one patient （7.1%） in group B （P = 0.001）. Sustained virological response was observed in 11 patients （64.7%） in group A and in one patient in group B （7.1%）. Biochemical response parameters normalized in 10/14 patients （71.4%） at the end of the treatment. ALT levels in group B were initially high in six patients and normalized in one of them （25%） at the end of the 48 wk. In five patients （22.7%） therapy had to be stopped at mo 4 due to complications of weakness, anemia, and bleeding. CONCLUSION： SVR could be achieved in 64.7% of patients on hemodialysis with chronic hepatitis C by a treatment with peglyated-interferon α-2a. Group A had a significantly better efficacy compared to the control group B, but the side effects need to be concerned.

Efficacy and safety of combined directly acting antivirals for treatment of Chinese chronic hepatitis C patients in a real-world setting

AIM To assess the efficacy and safety of combined directly acting antivirals(DAAs) for the treatment of Chinese chronic hepatitis C(CHC) patients in a real-world setting.METHODS Hospitalized CHC patients who were treated with DAAs at Peking University First Hospital between January 2015 and December 2016 were enrolled. Samples and clinical data were collected at 0 wk, 2 wk, 4 wk, 8 wk, 12 wk, or 24 wk during DAAs treatment and at 4 wk, 12 wk, and 24 wk after the end of treatment. RESULTS Fifty-four patients who underwent DAAs treatment were included in our study, of whom 83.3%(45/54) achieved rapid virological response at 2 wk after treatment initiation(RVR 2) and 94.4%(51/54)achieved sustained virological response at 24 wk after the end of treatment(SVR 24). Serum creatinine and uric acid levels at the end of treatment were significantly increased compared with baseline levels(83.6 ± 17.9 vs 88.8 ± 19.4, P 01 < 0.001; 320.8 ± 76.3 vs 354.5 ± 87.6, P 01 < 0.001), and no significant improvements were observed at 24 w after the end of treatment(83.6 ± 17.9 vs 86.8 ± 19.1, P 02 = 0.039; 320.8 ± 76.3 vs 345.9 ± 89.4, P 02 = 0.001). The total frequency of adverse events(AEs) during treatment was 33.3%(18/54), with major AEs being fatigue(16.7%), headache(7.4%), anorexia(7.4%), and insomnia(5.6%). CONCLUSION Though based in a small cohort of patients, the abnormal changes in renal function indices and relative high frequency of AEs during combined DAAs treatment should be taken as a note of caution.

Variable expression of cystatin C in cultured trans-differentiating rat hepatic stellate cells

AIM. To study the expression of cystatin C （CysC）, its regulation by transforming growth factor-β1 （TGF-β1） and platelet-derived growth factor （PDGF） and the potential interference of CysC with TGF-β1 signaling in this special cell type. METHODS： We evaluated the CysC expression in cultured, profibrogenic hepatic stellate cells and transdifferentiated myofibroblasts by Northern and Western blotting and confocal laser scanning microscopy. RESULTS： CysC was increased significantly in the course of trans-differentiation. Both TGF-β1 and PDGFBB suppressed CysC expression. Furthermore, CysC secretion was induced by the treatment with TGF-β1. Although CysC induced an increased binding affinity of TGF-β receptor type Ⅲ （beta-glycan） as assessed by chemical cross-linking with [^125I]-TGF-β1, it did not modulate TGF-β1 signal transduction as shown by evaluating the Smad2/3 phosphorylation status and [CAGA]-MLP-luciferase reporter gene assay. Interestingly, the shedding of type Ⅲ TGF-β receptor beta-glycan was reduced in CysC-treated cells. Our data indicated that CysC expression was upregulated during transdifferentiation. CONCLUSION： Increased CysC levels in the serum of patients suffering from liver diseases are at least partially due to a higher expression in activated hepatic stellate cells. Furthermore, TGF-β1 influences the secretion of CysC, highlighting a potentially important role of cysteine proteases in the progression of hepatic fibrogenesis.

Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation

AIM: To investigate differences in tolerability and response to treatment in compensated cirrhotic patients affected by hepatitis C virus (HCV) infection before and after liver transplantation. METHODS: Forty-three HCV non-liver transplanted (LT) cirrhotics (mean age 55 ± 8 years, 65.1% male, Child-Pugh-A, genotype 1-4: 65.1%, 2-3: 34.9%) and 17 LT recipients with recurrent HCV-related cirrhosis (mean age 57 ± 9 years, 88.2% male, Child-Pugh-A, genotype 1-4: 76.5%, 2-3: 23.5%) were included in the analysis from retrospective series. All patients received recombinant or pegylated interferon plus ribavirin at a standard dose and duration. Adverse events were recorded and classified according to the Common Terminology Criteria for Adverse Events. The mean duration of follow-up was of 4.3 ± 1.8 years after the end of the treatment. RESULTS: An early virological response (EVR) was achieved in 30/43 (69.8%) non-LT and in 8/17 (47.1%) LT cirrhotics, a sustained virological response (SVR) in 18/43 (41.9%) and 5/17 (29.4 %), respectively. No sta- tistical difference was observed in EVR and SVR rates between the two groups. Among HCV non-LT cirrhotics, 6/43 (13.9%) discontinued the treatment prematurely, 11.6% of them receiving ≤ 80% of treatment; 8/17 (47%) LT cirrhotics withdrew the treatment, 35.2% of them receiving ≤ 80% of treatment. If compared with LT-ones (P = 0.015), an higher risk of treatment discontinuation could affect LT cirrhotics, who undergo more frequently ≤ 80% of treatment (P = 0.05). None of the non-LT cirrhotics died after the end of the treatment. With no regards to the achievement of SVR, LT cirrhotic patients showed a reduced survival in respect to non-LT ones (87% at 1 year, 76% at 3 and 5 years after the end of treatment).CONCLUSION: HCV antiviral treatment is equally effective in compensated cirrhotics both before and after LT, which patients show a higher risk of premature treatment withdrawal and a reduced survival, independently of the achievement of SVR.

Nuclear Safety Functions of ITER Gas Injection System Instrumentation and Control and the Concept Design

The ITER Gas Injection System（GIS） plays an important role on fueling, wall conditioning and distribution for plasma operation. Besides that, to support the safety function of ITER, GIS needs to implement three nuclear safety Instrumentation and Control（I＆C） functions.In this paper, these three functions are introduced with the emphasis on their latest safety classifications. The nuclear I＆C design concept is briefly discussed at the end.

Safety and efficacy of anti-tumor necrosis factors α in patients with psoriasis and chronic hepatitis C

Up to date,in literature,it is still debated the role of anti-tumor necrosis factors(TNF)-α treatments in hepatitis C virus(HCV) patients.TNF-α performs a lot of functions,it is an important pro-inflammatory cytokine and it is involved in the host's immunity.Since TNF-α is implicated in the apoptotic signaling pathway of hepatocytes infected by HCV,anti TNF-α therapy may increase the risk of viral replication or their reactivation.However the treatment of anti TNF-α could have a healthful role because TNF-α appears to be engaged in the pathogenesis of liver fibrosis,inducing apoptotic pathways.We describe the case of a patient with plaquetype psoriasis and concomitant chronic HCV,who was treated successfully with anti-TNF agents simultaneously to cyclosporine without sign of reactivation of HCV and increase of liver enzymes.Our personal experience shows that anti-TNF-α agents are not only effective but also safe.Furthermore the combination therapy of cyclosporine and anti-TNF-α appears to be well-tolerated and able to reduce the amount of liver enzymes as well as HCV-viral-load.However systematic,large-scale studies with long follow-ups will be needed to confirm our results,in association with close liver function monitoring.

Hepatic decompensation/serious adverse events in post-liver transplantation recipients on sofosbuvir for recurrent hepatitis C virus

AIM: To determine the safety profile of new hepatitis C virus (HCV) treatments in liver transplant (LT) recipients with recurrent HCV infection.METHODS: Forty-two patients were identified with recurrent HCV infection that underwent LT at least 12 mo prior to initiating treatment with a Sofosbuvir-based regimen during December 2013-June 2014. Cases were patients who experienced hepatic decompensation and/or serious adverse events (SAE) during or within one month of completing treatment. Controls had no evidence of hepatic decompensation and/or SAE. HIV-infected patients were excluded. Cumulative incidence of decompensation/SAE was calculated using the Kaplan Meier method. Exact logistic regression analysis was used to identify factors associated with the composite outcome.RESULTS: Median age of the 42 patients was 60 years [Interquartile Range (IQR): 56-65 years], 33% (14/42) were female, 21% (9/42) were Hispanic, and 9% (4/42) were Black. The median time from transplant to treatment initiation was 5.4 years (IQR: 2.1-8.8 years). Thirteen patients experienced one or more episodes of hepatic decompensation and/or SAE. Anemia requiring transfusion, the most common event, occurred in 62% (8/13) patients, while 54% (7/13) decompensated. The cumulative incidence of hepatic decompensation/SAE was 31% (95%CI: 16%-41%). Risk factors for decompensation/SAE included lower pre-treatment hemoglobin (OR = 0.61 per g/dL, 95%CI: 0.40-0.88, P < 0.01), estimated glomerular filtration rate (OR = 0.95 per mL/min per 1.73 m2, 95%CI: 0.90-0.99, P = 0.01), and higher baseline serum total bilirubin (OR = 2.43 per mg/dL, 95%CI: 1.17-8.65, P < 0.01). The sustained virological response rate for the cohort of 42 patients was 45%, while it was 31% for cases.CONCLUSION: Sofosbuvir/ribavirin will continue to be used in the post-transplant population, including those with HCV genotypes 2 and 3. Management of anemia remains an important clinical challenge.

基于G1-C-OWA法组合赋权的堤防工程安全评价

为了更好掌握堤防工程的安全状况,及时进行补强加固,在总结堤防安全相关资料信息与文献基础上,构建了堤防工程安全评价指标体系;通过基于C-OWA算子优化的G1法与CRITIC法对指标进行主客观赋权,削弱主观判断影响;根据堤防工程存在资料信息缺失的特点,利用混合型中心点三角白化权函数的灰色定权聚类法构建堤防工程安全评价模型。结合实际工程案例表明,该评价模型合理可行,具有较强的工程实用意义。

Limit equilibrium method(LEM) of slope stability and calculation of comprehensive factor of safety with double strength-reduction technique

When the slope is in critical limit equilibrium(LE) state, the strength parameters have different contribution to each other on maintaining slope stability. That is to say that the strength parameters are not simultaneously reduced. Hence, the LE stress method is established to analyze the slope stability by employing the double strengthreduction(DSR) technique in this work. For calculation model of slope stability under the DSR technique, the general nonlinear Mohr–Coulomb(M–C) criterion is used to describe the shear failure of slope. Meanwhile, the average and polar diameter methods via the DSR technique are both adopted to calculate the comprehensive factor of safety(FOS) of slope. To extend the application of the polar diameter method, the original method is improved in the proposed method. After comparison and analysis on some slope examples, the proposed method's feasibility is verified. Thereafter, the stability charts of slope suitable for engineering application are drawn. Moreover, the studies show that:(1) the average method yields similar results as that of the polardiameter method;(2) compared with the traditional uniform strength-reduction(USR) technique, the slope stability obtained using the DSR techniquetends to be more unsafe; and(3) for a slope in the critical LE state, the strength parameter φ, i.e., internal friction angle, has greater contribution on the slope stability than the strength parameters c, i.e., cohesion.

基于C-IASI白车身结构正面和侧面碰撞分析与优化

某款已经量产的SUV在前期设计开发过程中,未充分考虑C-IASI规程中车内乘员安全工况,不能满足最新C-IASI工况设计目标。以本款SUV白车身为研究对象,建立有限元模型按C-IASI规程的验证工况进行车内乘员安全的受力分析和试验摸底。依据车身骨架结构的力学特性及分析结果进行骨架结构优化设计,最终经过有限元分析及实车验证达到设计目标;通过有限元分析方法和方案优化,可以在数据设计阶段有效改善车身安全性,大大缩短车身开发周期和成本。

In-Silico Analysis &In-Vivo Results Concur on Glutathione Depletion in Glyphosate Resistant GMO Soy, Advancing a Systems Biology Framework for Safety Assessment of GMOs

This study advances previous efforts towards development of computational systems biology, in silico, methods for biosafety assessment of genetically modified organisms (GMOs). C1 metabolism is a critical molecular system in plants, fungi, and bacteria. In our previous research, critical molecular systems of C1 metabolism were identified and modeled using CytoSolve?, a platform for in silico analysis. In addition, multiple exogenous molecular systems affecting C1 metabolism such as oxidative stress, shikimic acid metabolism, glutathione biosynthesis, etc. were identified. Subsequent research expanded the C1 metabolism computational models to integrate oxidative stress, suggesting glutathione (GSH) depletion. Recent integration of data from the EPSPS genetic modification of Soy, also known as Roundup Ready Soy (RRS), with C1 metabolism predicts similar GSH depletion and HCHO accumulation in RRS. The research herein incorporates molecular systems of glutathione biosynthesis and glyphosate catabolism to expand the extant in silico models of C1 metabolism. The in silico results predict that Organic Soy will have a nearly 250% greater ratio of GSH and GSSG, a measure of glutathione levels, than in RRS that are glyphosate-treated glyphosate-resistant Soy versus the Organic Soy. These predictions also concur with in vivo greenhouse results. This concurrence suggests that these in silico models of C1 metabolism may provide a viable and validated platform for biosafety assessment of GMOs, and aid in selecting rational criteria for informing in vitro and in vivo efforts to more accurately decide in the problem formulation phase whose parameters need to be assessed so that conclusion on “substantial equivalence” or material difference of a GMO and its non-GMO counterpart can be drawn on a well-grounded basis.

基于2021版C-NCAP对MPDB工况的车身结构优化

为提高汽车碰撞安全性能,满足2021版C-NCAP的评价要求,首先,根据中国汽车技术研究中心2021版CNCAP管理规则,对新增的MPDB工况进行了解读。然后,基于某新开发SUV车型采用LS-DYNA软件进行了有限元仿真分析,发现车身加速度、加速度平台40g以上持续时间以及兼容性罚分未满足设计要求。随后,进一步对仿真结果的车身变形模式进行了分析,发现未满足设计要求的原因主要为纵梁异常折弯、前防撞梁刚度弱以及壁障与车身的有效接触面积不足。基于分析结果对车辆前端包括前防撞梁、吸能盒、前纵梁以及小腿防撞梁进行了结构优化,并将优化方法代入正面100%重叠刚性壁障碰撞工况进行校核。最后,从车身结构变形模式、车身加速度曲线、壁障兼容性罚分这3方面进行了仿真试验对标。结果表明:加速度峰值由45.9g降为41.7g,加速度平台40g以上持续时间由7.4 ms降为2.85 ms,兼容性罚分由3.9降为2.71,车身变形模式和壁障变形均匀性得到明显改善;综合评估该优化方案,车身结构耐撞性能满足2021版MPDB工况五星得分规划要求,优化方案对正面100%重叠刚性壁障碰撞工况影响很小且满足设计要求;仿真与试验结果的吻合度在84%以上,证明了仿真结果的准确性。在此研究的基础上基于MPDB工况的特点和要求提出了5项优化设计思路,为后续车型开发提供参考。

格卡瑞韦/哌仑他韦治疗HCV感染者和人类免疫缺陷病毒合并HCV感染者疗效及安全性研究

目的评估应用格卡瑞韦/哌仑他韦治疗丙型肝炎病毒(HCV)感染和人类免疫缺陷病毒(HIV)合并HCV感染者的疗效及安全性。方法2021年4月~2021年12月凉山彝族自治州越西县第一人民医院诊治的HCV感染者25例和HIV合并HCV感染者27例,均接受格卡瑞韦/哌仑他韦治疗8~12周,随访12周。结果两组静脉注射毒品感染HCV的比率分别为60.0%和63.0%;HCV感染者实现持续病毒学应答(SVR)为92.0%,而HIV合并HCV感染者为88.9%,两组间差异无统计学意义(P=1.000);两组患者对该药耐受性良好,均未发生不良事件导致的治疗方案调整或中止。结论应用格卡瑞韦/哌仑他韦治疗HCV感染者和HIV合并HCV感染者具有较好的近期疗效和较高的安全性。